| 12 September 2024 |
|
ALLIANCE PHARMA
("Alliance", "Company" or the "Group")
Notification of Half Year Results
Alliance Pharma plc (AIM: APH), the international healthcare group, will announce its interim results for the six months ended 30 June 2024 on Monday 30 September 2024.
A meeting for analysts will be held at 10.00am on the day of the results at Burson Buchanan, 107 Cheapside, London EC2V 6DN. To register attendance at the meeting, analysts should contact alliancepharma@buchanan.uk.com
A live webcast of the analyst meeting will be accessible via the following link: https://stream.buchanan.uk.com/broadcast/66def9f76b479f7c8e789e9a
Following the meeting, a recording of the webcast will be made available at the investor section of Alliance's website, https://www.alliancepharmaceuticals.com/investors
For further information:
| Alliance Pharma plc | + 44 (0)1249 466966 |
| Cora McCallum, Head of Investor Relations & Corporate Communications | + 44 (0)1249 705168 |
| | |
| | |
| Burson Buchanan | + 44 (0)20 7466 5000 |
| Mark Court / Sophie Wills | |
| | |
| | |
| Deutsche Numis (Nominated Adviser and Joint Broker) | + 44 (0)20 7260 1000 |
| Freddie Barnfield / Duncan Monteith / Sher Shah | |
| | |
| Investec Bank plc (Joint Broker) | + 44 (0)20 7597 5970 |
| Patrick Robb / Ben Lawrence / Maria Gomez de Olea | |
About Alliance
Alliance Pharma plc (AIM: APH) is a growing consumer healthcare company. Our purpose is to empower people to make a positive difference to their health and wellbeing by making our trusted and proven brands available around the world.
We deliver organic growth through investing in our priority brands and channels, in related innovation, and through selective geographic expansion to increase the reach of our brands. Periodically, we may look to enhance our organic growth through selective, complementary acquisitions.
Headquartered in the UK, the Group employs around 290 people based in locations across Europe, North America, and the Asia Pacific region. By outsourcing our manufacturing and logistics we remain asset-light and focused on maximising the value we can bring, both to our stakeholders and to our brands.
For more information on Alliance, please visit our website: www.alliancepharmaceuticals.com
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.